Clue Unveils Our Year In Cycles: A Candid Look at How We Bled, Felt, Loved and Lived in 2025

Clue Unveils Our Year In Cycles: A Candid Look at How We Bled, Felt, Loved and Lived in 2025




Clue Unveils Our Year In Cycles: A Candid Look at How We Bled, Felt, Loved and Lived in 2025

  • Exclusive cycle tracking data reveals 280 million days of bleeding were tracked across the globe in the last 12 months
  • App users logged 34 million sex sessions and 4.4 million orgasms across 2025
  • 44.6 million days of cramps were recorded, the equivalent of 122,000 years of pain if shouldered by one person
  • Our Year in Cycles is an annual snapshot of hormones and health, with the aim of tackling taboo and stigma around the menstruation conversation

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) — Clue, the #1 women-led period and cycle tracker trusted by over 100 million people worldwide, today releases Our Year In Cycles – an annual analysis of how women and people with cycles tracked their lives, bodies and emotions throughout 2025.

Based on hundreds of millions of anonymized logs made in the Clue app, this year’s edition breaks down the real rhythms behind our moods, cravings, orgasms, sleep (or lack of it), stress and the 280 million days we collectively spent bleeding – the equivalent of one person experiencing nearly 767,000 years of periods.

“Menstrual health affects over half the population, yet the cultural taboo around it has left generations without the knowledge or support they deserve,” commented Rhiannon White, CEO of Clue. Our Year In Cycles reveals how profoundly our hormonal patterns intersect with our daily lives bringing what has been hidden into the light – not to sensationalize it, but to normalize it. By transforming millions of lived experiences into clear, accessible insights, Our Year In Cycles makes it possible for all of us to talk about hormones, pain, pleasure and wellbeing with the same openness we bring to other life topics.”

From the 280 million days of bleeding tracked, to the 44.6 million days of cramps logged, Our Year in Cycles demonstrates the world’s emotional and hormonal highs and lows through the bodies of millions of women and people with cycles.

Key Global Insights from Our Year In Cycles:

Ringing in the New Year with sex and fantasies

New Year’s Day came in hot – literally. It was the single most popular day of 2025 for high sex drive, sex, orgasms and fantasies, suggesting that Clue users kicked off the year with a surge of intimacy. Whether it’s the psychological clean-slate effect, post-party closeness or simply having a rare moment of rest and privacy, the data show that January 1st isn’t just for resolutions.

On the flip side, September 10th was reported as the year’s global ‘not tonight’ moment, as the day Clue tracked the lowest libido.

Gen Z leads the pleasure revolution

Half of all tracked orgasms in 2025 came from 18-24 year olds, establishing Gen Z as the most vocal generation when it comes to pleasure.

Gen Z also prove to be the masters of self-stimulation, accounting for more than half (58%) of all entries. In fact, Gen Z users tracked masturbation and fantasies at the highest rate, with masturbation being tracked 20% more often and fantasies 40% more often, by comparison to other age groups. Meanwhile, data show that millennials (25-34 year olds) lead the way with sex toy action.

The findings indicate that young adults are rewriting the script, turning pleasure stigma into pleasure literacy.

But pleasure isn’t logged as often as sex…

Clue users logged 34 million sex sessions and 4.4 million orgasms across 2025, highlighting that pleasure is still under-tracked and under-discussed compared with sex itself, revealing how deeply the pleasure gap is embedded in culture.

The Philippines topped the “most sex” and “most orgasms” lists, sparking new cultural questions about approaches to intimacy in different geographies.

Traditional period products still dominate despite growing appetite for reusable methods

Despite the hype around reusable period products, 2025 was still the year of the pad, used by nearly two-thirds of Clue users (63%), with tampons used by 14% comparatively. The data suggest that real-life period habits aren’t changing as fast as the headlines, with most people sticking with what feels safe, familiar and reliable. With rising concerns around tampon ingredients and contamination making global news, it’s clear that trust, not trends, is driving product choices and the shift toward reusables is more slow evolution than sudden revolution.

Period pain remains one of the most universal (and normalized) experiences

Clue users logged a staggering 44.6 million days of cramps, the equivalent of 122,000 years of pain if shouldered by one person. Cramps were the most common pain logged (35%), followed by breast tenderness (12%), lower back pain (11%) and headaches (10%). Almost one in five cramps (19%) were rated severe. The key takeaway? Menstrual pain isn’t minor. It’s massively under-recognized and it’s time the world treated it with the seriousness it deserves.

Hormones and days of the week shaped our emotional landscape – and unsurprisingly politics didn’t help…

Mood swings topped the charts over the past year, accounting for almost a fifth (17%) of all tracked feelings. The emotional peak of the year was revealed as 6th November 2024, when users worldwide recorded their saddest, angriest, and most stressed moods.

Weekly patterns painted a familiar yet striking picture: Mondays are (unsurprisingly) the gloomiest, Thursdays the most stressful, Saturdays the happiest, most energized and most creative, and Sundays the most popular day for sex. So much for a day of rest…

Sleep was scarce, with over a third waking up tired

Across millions of sleep logs, 38% recorded waking up tired, 15% struggled to fall asleep, 14% slept restlessly and 10% experienced vivid dreams – perhaps hormones, stress and modern life are a recipe for a global sleep deficit?

The good news? We’re proactive about our reproductive health

Nearly a quarter of a million OBGYN appointments were recorded throughout the year, with 18-34 year olds making up 84% of all appointments. Similarly, 18-34 year olds are 70% more likely to track STI check ups than other demographic groups – a strong sign that stigma is decreasing and sexual health checks are becoming more routine.

Dr Charis Chambers, The Period Doctor and Chief Medical Officer at Clue, shared her view on the data: “When millions of people track their cycles, we gain a clearer picture of how hormones influence sleep, mood, energy, sex and pain. Our Year in Cycles isn’t just about periods, it’s about connecting the dots between our bodies and the experiences that are so often dismissed or stigmatized. Severe cramps, mood shifts, low energy, disrupted sleep are deeply common and valid. By representing real people with real data, we can help reduce shame and stigma around the menstrual health conversation.”

Clue’s data shows that cycles aren’t just about periods – they shape moods, sleep, cravings, intimacy, pain, and the rhythms of daily life. From the highs of orgasms and creativity to the lows of cramps and sleepless nights, the data turns millions of personal experiences into a collective story.

By making the invisible visible, Clue is helping to normalize conversation, break taboos, and empower women and people with cycles to understand, care for, and celebrate their bodies – every single day of the year.

Head to www.helloclue.com for more information and to download the app.

About Our Year In Cycles

Our Year In Cycles is an annual analysis including only aggregate data from Clue by Clue users over 18 years from October 2024 – October 2025.

About Clue
Clue is the #1 women-led period and cycle tracker, loved by over 100 million women and people with cycles around the world.

Beyond period tracking, Clue helps you turn your cycle into a powerful tool to help navigate your health journey by making sense of your hormones and discovering your unique patterns.

Whether you want to simply understand your cycle, try to conceive,
track your pregnancy, or navigate perimenopause, Clue is your intelligent, science-backed, data-driven health guide.

Join the movement that’s changing the future of female health, one data point at a time. Try Clue free, today.

Press
For more information about this particular press release, contact press@helloclue.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bf10e1d8-32b7-4c8a-ad07-5d19ec1bb64c

Opterion Health AG Announces Appointment of Andreas Schuh as Chief Financial Officer

Opterion Health AG Announces Appointment of Andreas Schuh as Chief Financial Officer




Opterion Health AG Announces Appointment of Andreas Schuh as Chief Financial Officer

Andreas Schuh, Chief Financial Officer, Opterion Health AG

MUTTENZ, Switzerland, Dec. 01, 2025 (GLOBE NEWSWIRE) — Opterion Health AG, a clinical-stage biopharmaceutical company pioneering innovation in peritoneal dialysis (PD), is pleased to announce the appointment of Andreas Schuh as Chief Financial Officer (CFO), effective December 1, 2025.

Andreas Schuh joins Opterion with over 20 years of leadership experience across biotech, pharma, and medical devices. He has held senior finance and operations roles at Nuclidium, Jeito, Roivant, Novartis, and Alcon, where he drove major fundraising rounds, managed multi-billion R&D budgets, and delivered significant margin improvements through strategic cost management and governance. Most recently, as CFO at Nuclidium, Andreas closed a CHF 78 million Series B round. His track record includes building high-performing teams, establishing financial infrastructure across geographies, and driving sustainable growth in innovative healthcare companies.

“We are delighted to welcome Andreas to Opterion at this pivotal time,” said Peter Reinemer, CEO of Opterion Health AG. “His deep financial expertise, hands-on leadership, distinguished track record in fundraising, and proven ability to scale organizations will be invaluable to Opterion. Andreas’s appointment further strengthens our leadership team as we build on recent milestones, including the submission of our Clinical Trial Application (CTA) for OPT101 and the expansion of our Board of Directors.”

Andreas Schuh commented: “I am excited to join Opterion Health at such a dynamic stage in its journey. The company’s mission to transform dialysis care and its commitment to meaningful innovation for patients truly resonate with me. I look forward to working with the team to help realize the Opterion vision and deliver value for patients, partners, and shareholders.”

Opterion would also like to extend its sincere thanks to Michelle Mauri, who has served as interim CFO during this transition. Michelle has provided outstanding support and leadership, and we are grateful for her continued contributions as she transitions to a new strategic role within the company, focusing on business operations and organizational development.

These leadership developments, alongside the recent CTA submission for OPT101, which represents the first innovation of its kind in over 30 years in the field of PD, mark important steps in the Opterion vision to transform dialysis care and set a new gold standard in PD.

About Opterion Health AG
Opterion Health AG is a Swiss-based biopharmaceutical company focused on transforming renal care through the development of novel therapies for peritoneal dialysis patients. Its lead candidate, OPT101, is designed to improve the quality of life of patients undergoing peritoneal dialysis and to change the odds of PD outcomes for those who rely on life-saving treatments.

For further information, please contact:
info@opterion.com
www.opterion.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d779996d-1a69-443d-8594-3d28e9f9a6f0

Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision

Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision




Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision

November 30, 2025

  • Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1]
  • CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4]

Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Verida, the world’s first detector-based spectral CT fully powered by AI. This marks a transformative milestone in CT, with AI optimizing the entire imaging chain – lowering system noise, elevating image quality, and accelerating clinical workflow.

With over 800 global installations and supported by over 800 peer-reviewed publications, Philips’ spectral CT uses PACS-native delivery and has been fully embedded into clinical workflow. Spectral CT measures how tissues absorb different x-ray energy levels, enabling differentiation of materials that appear identical on conventional CT. Philips has pioneered detector-based spectral CT, delivering multiple spectral results from a single scan with no tradeoffs in performance or scan time.

Now, by integrating AI across the imaging chain, from acquisition to reconstruction, Philips Verida generates industry-leading, superior spectral image quality with minimal noise, in addition to high-definition conventional images. With its full AI capabilities, Verida can achieve dramatic dose reduction [5] without compromising image quality and reduce energy consumption by up to 45% [6].

“The clinical benefits of Verida will fundamentally change my approach to cardiac imaging,” said Prof. Eliseo Vañó Galván, cardiovascular radiologist, Chairman of the CT & MR Department at Hospital Nuestra. Sra. Del Rosario, Madrid, Spain. “With more comprehensive insights in every cardiac CT, I plan to make spectral imaging routine for all patients – building toward a fully spectral CT department. We evaluated many systems, including photon-counting CT, but chose Philips because it delivers the precision we need in a streamlined, easy-to-use platform. The result is greater diagnostic confidence and the potential to reduce the need for invasive angiograms – not just in cardiology, but across other clinical areas as well [7].”

Verida reconstructs 145 images per second, so entire exams automatically appear in less than 30 seconds – 2× faster than before and enabling up to 270 exams every day [8]. Building on Philips’ proprietary Spectral Precise Image technology – a deep learning AI reconstruction engine combined with advanced spectral imaging – and its third-generation Nano-panel Precise dual-layer detector with intrinsic noise reduction optimized for AI, Verida is designed to deliver faster, more dose-efficient spectral reconstructions. This enables clinicians to access rich spectral information from a single scan.

“Combining the latest advances in our proven spectral CT technology with AI, our flagship Verida CT system is designed to set a new standard in superior image quality and accelerated scans which are fully embedded in the radiology workflow, all to help clinicians detect and characterize disease earlier, reduce variability in diagnoses, and support efficient treatment pathways – in a single scan,” said Dan Xu, Business Leader of CT at Philips. “While photon-counting CT adds complexity, is yet to move from the research arena into clinical practice, Philips spectral CT has been a clinical workhorse for more than a decade and delivers comparable or better clinical outcomes, standing up to the most demanding throughput and at significantly lower total cost of ownership”.

Verida extends Philips’ software-defined CT approach, pairing AI-driven spectral precision to advance both clinical and operational outcomes. Built for high-demand environments, it streamlines workflows, reduces repeat scans, and delivers consistently sharp imaging across all care pathways.

Philips is debuting Verida at RSNA 2025, with availability in select markets beginning in 2026 [9].

[1] Data on file. 
[2] CE marked and 510(k) pending. Not currently available for sale in the US.
[3] Andersen MB et al. Impact of spectral body imaging in patients suspected for occult cancer: a prospective study of 503 patients. Eur Radiol2020. doi.org/10.1007/s00330-020-06878-7
[4] Andersen MB et al. Economic impact of spectral body imaging in the diagnosis of patients suspected of occult cancer. Insights into Imaging 2021. doi.org/10.1186/s13244-021-01116-0. Results of customer testimonies are not predictive of results in other cases, where results may vary.
[5] Dose reduction assessments were performed using reference body protocol. In clinical practice, the use of Spectral Precise Image may reduce CT patient dose depending on the clinical task, patient size, and anatomical location. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task.
[6] Based on Axial Body 3D Scan with 80% dose reduction. Energy savings for system preparation is not included.
[7] Spectral CT Verida Premium up to 270 (4 CIRS config) exams a day (16 hours dual shift working day) meeting the needs of radiology departments with extended work hours and very high patient throughput.
[8] The statements of the clinician reflect independent opinion and are not intended to imply product performance prior to regulatory clearance.
[9] Pending regulatory clearance.

For further information, please contact:

Anna Hogrebe
Philips Global External Relations
Tel.: +1 416 270 6757
E-mail: anna.hogrebe@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform




Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform

November 30, 2025

Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1]

Amsterdam, the Netherlands, and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry’s first helium-free 3.0T magnet at RSNA 2025. A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have significant impact for health providers and patients.

3.0T MRI systems are the most advanced MRI magnet technology in widespread use, providing high-resolution imaging for research and the most complex clinical cases. These systems excel in capturing the most intricate workings of the body, especially the brain, blood vessels, muscles and joints. Philips has led the development of helium-free MRI since 2018, with more than 2,000 of its 1.5T BlueSeal MRI systems installed worldwide, saving more than 6 million liters of liquid helium to date [3]. The company is now bringing the same benefits to 3.0T MRI, eliminating the need for helium refills and vent pipes – reducing siting complexity, installation time, and total lifecycle risk.

“With BlueSeal Horizon we’re freeing MRI from dependence on a valuable resource the world can’t replace and bringing advanced diagnostic capabilities to people previously out of reach,” said Ioannis Panagiotelis, PhD, Business Leader, MR at Philips. “But more than that, BlueSeal Horizon is an entirely new 3.0T innovation platform that combines breakthroughs in hardware with AI-powered software, eliminating the trade-off between imaging speed and precision and improving outcomes for both practitioners and patients.”

Next-generation clinical AI on the Philips BlueSeal Horizon platform
Philips will bring next-generation clinical AI into everyday practice with the introduction of its new BlueSeal Horizon MR platform [1], simplifying workflows, enhancing diagnostic precision, and expanding access to advanced imaging. Key AI-powered innovations will include:

SmartPlanning: Expanding to include cardiac imaging, this AI-driven feature will automate time-consuming planning steps. What once required multiple manual actions can now be completed in a single click, achieving automated planning in as little as 30 seconds.

Real-time Scan Preview: Powered by NVIDIA’s accelerated computing platform and Open Models (Segment and Generate), this innovation aims to enable faster 3D image reconstruction, denoising, and artifact reduction, so radiologists can preview scans, adjust image quality and speed parameters in real time, and optimize workflow efficiency for more timely diagnosis.

SmartSpeed Precise: Dual AI technology will enable scans up to three times faster and images up to 80% sharper [4], helping clinicians capture more detail in less time.

SmartReading: This tool will integrate cloud-based AI reading and reporting tools directly on the MR system, specifically for neurology and oncology applications.

Together, these innovations will bring advanced clinical AI to the point of care, helping radiology teams achieve faster, sharper, and more consistent imaging results, supporting confident, first-time-right diagnosis.

[1] 3.0T BlueSeal Horizon is ‘Work in Progress’ and not available in any jurisdiction. It is not for sale in the USA. Its future availability cannot be ensured.
[2] Helium-free operations. 7 liters of helium is permanently enclosed in the cryogenic circuit.
[3] The amount of liquid helium saved is a calculation compared to a previous generation magnet with 1500 liters of helium.
[4] Compared to Philips SENSE/ C-SENSE imaging SmartSpeed Precise is already available on current 3.0T systems.

For further information, please contact:

Jayme Maniatis
Philips Global External Relations
Tel. : +1 617 894 8368
E-mail: jayme.maniatis@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

At RSNA 2025, ASCEND Cardiovascular and Konica Minolta Healthcare Announce Partnership to Deliver a Best-in-Class Enterprise Imaging Solution that Elevates Cardiovascular Care

At RSNA 2025, ASCEND Cardiovascular and Konica Minolta Healthcare Announce Partnership to Deliver a Best-in-Class Enterprise Imaging Solution that Elevates Cardiovascular Care




At RSNA 2025, ASCEND Cardiovascular and Konica Minolta Healthcare Announce Partnership to Deliver a Best-in-Class Enterprise Imaging Solution that Elevates Cardiovascular Care

WAYNE, N.J. and SPRINGFIELD, Ill., Nov. 30, 2025 (GLOBE NEWSWIRE) — ASCEND Cardiovascular, a leading provider of purpose-built enterprise imaging for cardiology, and Konica Minolta Healthcare Americas, Inc., a world-class provider of medical diagnostic imaging and healthcare IT solutions, today announced a strategic partnership to deliver a unified and complete enterprise imaging solution for hospital cardiology departments and cardiology practices. The collaboration will address the critical need for integrated imaging platforms that empower clinicians across all cardiovascular subspecialties, without the compromises often found in all-encompassing, single-vendor systems.

Healthcare organizations today are increasingly seeking a unified imaging enterprise to break down the disconnected data silos that increase cost and complexity, and prevent access to a full, longitudinal patient imaging record. While many solutions promise a comprehensive approach, they often fail to meet the nuanced, high-stakes needs of specialized departments like cardiology. This partnership directly addresses this challenge by combining Konica Minolta’s cloud-based Exa® Enterprise solution with ASCEND’s deep expertise in multimodality cardiovascular imaging workflows. Konica Minolta Healthcare will showcase the multispecialty capabilities of Exa Enterprise at the 2025 Annual Meeting of the Radiological Society of North America (RSNA), being held November 30-December 3 in Chicago, in booth 2165.

By integrating ASCEND’s solutions into Exa Enterprise, the platform will provide specialized workflows and tools for cardiac patients, including invasive, non-invasive, adult and pediatric.

“For too long, cardiology has been treated as an afterthought in broader enterprise imaging strategies,” said Dr. Jeffrey Soble, CEO of ASCEND Cardiovascular. “The reality is, cardiology is an enterprise within the enterprise. Our solution creates a microcosm within the broader imaging ecosystem that is tailored to the unique needs of cardiovascular care and all its subspecialties. By partnering with Konica Minolta Healthcare, we are able to take that specialized, best-in-class approach and unify it with a trusted, enterprise-wide platform, offering healthcare systems the best of both worlds – complete, connected patient records without compromise.”

This partnership is a testament to Konica Minolta’s strategy of leveraging best-in-class partnerships to amplify Exa® PACS|RIS as a multi-specialty enterprise imaging offering. Exa Enterprise is designed to be an integrated ecosystem, and this collaboration with ASCEND further strengthens its ability to provide comprehensive solutions for cardiology.

“At Konica Minolta, we are committed to providing healthcare enterprises with solutions that enable better care,” said Kevin Chlopecki, COO of Konica Minolta Healthcare IT. “We believe a truly unified enterprise imaging platform should be built using a best-in-class approach, providing the right solution to meet specific customer challenges and goals. Our partnership with ASCEND Cardiovascular is a key step in this direction, as it offers a truly complete and uncompromised solution that fully empowers the complex, distinct workflows of cardiology.”

The unified solution is available to healthcare organizations seeking to adopt an integrated platform that supports their long-term clinical and operational goals.

About Konica Minolta Healthcare Americas, Inc.
Konica Minolta Healthcare is a world-class provider and market leader in medical diagnostic imaging and healthcare information technology. The company’s focus is to contribute to life-changing advances through the transformation of primary imaging, allowing the invisible to be seen. Primary imaging, the most commonly used medical imaging technologies, include X-ray and imaging management systems. By advancing these readily available technologies, we can bring greater diagnostic capabilities to the greatest number of people.

With 150 years of endless innovation, imaging is in Konica Minolta’s DNA. From roots as a camera and film manufacturer, the company has cultivated its own technologies and continues to evolve techniques for visualizing what is not visible. Innovation allows the company to be a strong strategic partner, understanding what value means to customers and how Konica Minolta’s innovations can address specific needs and lead to better decisions, sooner.

Konica Minolta Healthcare Americas, Inc., headquartered in Wayne, NJ, is a division of Konica Minolta, Inc. For more information on Konica Minolta Healthcare Americas, Inc., follow us on LinkedIn, X and Facebook, or visit https://healthcare.konicaminolta.us.

For more information from Konica Minolta Healthcare, please contact:
Mary Beth Massat                                                        
224.578.2388
mbmassat@massatmedia.com 

About ASCEND Cardiovascular
ASCEND Cardiovascular delivers a best-of-class cardiology imaging and IT solution designed to function as an “enterprise within the enterprise.” The ASCEND solution is purpose-built to meet the unique and complex workflows of cardiovascular care, including all invasive, non-invasive, and subspecialty needs for adult and pediatric patients.

For more information from ASCEND Cardiovascular, please contact:
Lisa Braunreuther
VP Sales and Marketing
lbraunreuther@ascendcv.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9b815dd9-b3cb-41e2-b626-62ada6a82d2b

Konica Minolta Healthcare Launches New Floor-Mounted Digital Radiography Systems at RSNA 2025

Konica Minolta Healthcare Launches New Floor-Mounted Digital Radiography Systems at RSNA 2025




Konica Minolta Healthcare Launches New Floor-Mounted Digital Radiography Systems at RSNA 2025

WAYNE, N.J. and CHICAGO, Nov. 30, 2025 (GLOBE NEWSWIRE) — Today at the 2025 Annual Meeting of the Radiological Society of North America (RSNA), Konica Minolta Healthcare Americas, Inc., announced the new KDR FMT and KDR FMT+ digital radiography (DR) systems. The KDR FMT and KDR FMT+ represent the next evolution in floor-mounted DR systems from Konica Minolta, designed to deliver high image quality, reliability and workflow efficiency. Konica Minolta Healthcare is exhibiting at RSNA 2025 in booth 2165.

Building on the trusted performance of the KDR product line, the KDR FMT and KDR FMT+ feature Konica Minolta’s signature tube-mounted control interface for a streamlined patient workflow. The KDR FMT is a fully manual system, ideal for low- to mid-volume imaging needs, offering precision and ease of use. The KDR FMT+ adds motorized movement and automatic detector tracking, making it the perfect solution for mid- to high-volume practices seeking to boost throughput and enhance patient care. The systems deliver imaging flexibility with a table that supports up to 700 lbs. and a wall stand for all imaging views required in general radiography, accommodating patients who are standing, sitting or lying on the table. Both systems are available with Konica Minolta’s ULTRA imaging software featuring REALISM image processing for exceptional contrast sensitivity and sharpness.

“Our newest DR systems further deliver on the high image quality and versatile imaging capabilities that the KDR family of DR systems is renowned for,” says Guillermo Sander, PhD, Marketing Director for Digital Radiography, Konica Minolta Healthcare. “The robust technology of the KDR FMT and KDR FMT+ is designed to maximize productivity, clinical confidence and economic value. Although robust and versatile, the solutions are easy-to-use and the tube-mounted control and image display provide more patient-facing time during the procedure to enhance patient care and their experience.”

About Konica Minolta Healthcare Americas, Inc.
Konica Minolta Healthcare is a world-class provider and market leader in medical diagnostic imaging and healthcare information technology. The company’s focus is to contribute to life-changing advances through the transformation of primary imaging, allowing the invisible to be seen. Primary imaging, the most commonly used medical imaging technologies, include X-ray and imaging management systems. By advancing these readily available technologies, we can bring greater diagnostic capabilities to the greatest number of people.

With 150 years of endless innovation, imaging is in Konica Minolta’s DNA. From roots as a camera and film manufacturer, the company has cultivated its own technologies and continues to evolve techniques for visualizing what is not visible. Innovation allows the company to be a strong strategic partner, understanding what value means to customers and how Konica Minolta’s innovations can address specific needs and lead to better decisions, sooner.

Konica Minolta Healthcare Americas, Inc., headquartered in Wayne, NJ, is a division of Konica Minolta, Inc. For more information on Konica Minolta Healthcare Americas, Inc., follow us on LinkedIn, X and Facebook, or visit https://healthcare.konicaminolta.us.

Contact:
Mary Beth Massat                                                        
224.578.2388
mbmassat@massatmedia.com 
https://healthcare.konicaminolta.us

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e3295dcc-3cbc-438c-81f9-82992049204a

DeepHealth Unveils Next-Generation Imaging Informatics and Clinical AI Solutions at RSNA 2025, Advancing a New Standard of AI-Powered Care

DeepHealth Unveils Next-Generation Imaging Informatics and Clinical AI Solutions at RSNA 2025, Advancing a New Standard of AI-Powered Care




DeepHealth Unveils Next-Generation Imaging Informatics and Clinical AI Solutions at RSNA 2025, Advancing a New Standard of AI-Powered Care

Company expands portfolio of novel AI-powered clinical and operational solutions delivering proven impact at scale—empowering breakthroughs in care through imaging

CHICAGO, Nov. 30, 2025 (GLOBE NEWSWIRE) — DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), today unveils an expanded portfolio at RSNA 2025, introducing next-generation imaging informatics and clinical AI solutions. The company is announcing new offerings and major enhancements across its portfolio, spanning disease detection, assessment and monitoring, remote scanning, image management and interpretation, center operations and AI orchestration—all designed to transform the imaging experience and advance population health.

“We are entering an era where AI-powered imaging can drive proactive, connected and more equitable care at global scale,” said Kees Wesdorp, President and CEO of RadNet’s Digital Health Division, DeepHealth. “At DeepHealth, we harness AI in an integrated, end-to-end approach across our portfolio with the intent to improve healthcare delivery. By unifying clinical and operational intelligence into DeepHealth OS and deploying scalable infrastructure that accelerates adoption, our technology becomes a catalyst to stage shift disease, expand patient access, elevate care teams and enhance operational efficiency. This is how we advance our mission of empowering breakthroughs in care through imaging.”

At RSNA this year, DeepHealth showcases an expanded, integrated portfolio of AI-powered solutions that demonstrate real-world impact in addressing key healthcare challenges such as disconnected patient engagement, strained workforce, inconsistent clinical outcomes and technology, data and workflow fragmentation. 

Unifying the Imaging Experience 
DeepHealth connects siloed tools, teams, and workflows to automate and orchestrate key tasks in the end-to-end imaging experience. DeepHealth showcases these solutions at RSNA through its enterprise imaging and operations portfolio that includes: 

  • Diagnostic Suite™1 — Accelerating and Automating Radiology: DeepHealth’s cloud-first enterprise image management and interpretation solutions deliver capabilities to automate and accelerate radiology at scale. New functionalities include cloud and hybrid data management with rapid migration, scalable ultra-fast streaming diagnostic viewer, AI-powered automated reporting and integrated advanced visualization, and enterprise AI orchestration in one seamless diagnostic environment. The recent acquisition of CIMAR UK brings additional advanced cloud image management and interoperability capabilities, supporting expanded deployments across the UK and Europe to accelerate AI-powered imaging, reporting and image-based screening. Components of Diagnostic Suite are actively deployed across RadNet sites and other customers, reflecting the Suite’s ability to deliver impact at scale in both outpatient and teleradiology environments. 
  • TechLive™ — Expanding Capacity and Access: TechLive is a multimodality, vendor-agnostic remote imaging and radiology management solution. With first-of-kind 510(k) clearance, it extends expert oversight across MR, Ultrasound, CT and PET/CT to accelerate onboarding, meet diverse workforce needs and expand access to advanced imaging.2 Deployment at RadNet to date has connected more than 400 scanners to TechLive, with results showing 42% fewer MR room closures, driving higher throughput and better patient and technologist experiences.2 TechLive is available as a standalone solution or through an expanded collaboration with GE HealthCare for use with its ultrasound products. In addition, TechLive can be combined with Alpha RT as remote-scanning technology with staffing and training expertise to support diverse workforce and operational needs. 
  • Operations Suite— Intelligent, Connected Imaging Operations: DeepHealth’s Operations Suite is an expanded, cloud-first suite of solutions that unifies scheduling, registration, billing, analytics and patient communication into a single environment. The Suite introduces new Patient Engagement solutions designed to improve communication, scheduling and adherence, along with agentic AI capabilities that enable automation to reduce administrative burden, optimize throughput and improve system-wide coordination. Operations Suite is being deployed across RadNet and other customer sites, as recently announced. Current customers leveraging DeepHealth RIS, previously eRAD RIS, will have the option to transition to Operations Suite through updated functionalities. 

Advancing Population Health with Clinical AI Solutions 
DeepHealth is introducing major advancements across its Population Health & Clinical AI portfolio, supported by expanded and new FDA clearances across multiple clinical areas. These innovations are designed to help stage shift disease, drive more timely and effective screening and diagnostic pathways, and expand patient access: 

  • DeepHealth Breast Suite — Elevating Breast Cancer Detection and Diagnosis: The new Breast Suite3 an AI-powered, FDA-cleared end-to-end suite of modular interoperable applications that significantly enhances diagnostic accuracy,4 improve workflow efficiency and drive greater standardization of care.4,5 Breast Suite delivers one of the industry’s most comprehensive breast cancer detection and diagnostic offerings by including breast cancer detection, risk asssesment,6 breast density, workflow tools and, in development, breast arterial calcification assessment.7 Breast Suite builds on organic innovation and technology integrated through the acquisition of iCAD to deliver a comprehensive new suite of solutions.
    • Breast Suite applications already support annually more than 10 million mammograms globally.
    • The largest real-world analysis of AI-powered breast cancer screening in the US recently published in Nature Health demonstrated the effectiveness of applications within Breast Suite to deliver a 21% increase in breast cancer detection rate in over 579,000 women, with consistent benefits across dense-breast and diverse patient populations.4
    • DeepHealth and GE HealthCare will expand their existing collaboration to include a wider suite of AI tools and extend access to the combined offering of their mammography systems with DeepHealth Breast Suite worldwide.
  • DeepHealth Thyroid Suite — Transforming Thyroid Ultrasound Imaging: The Thyroid Suite,8 an AI-powered suite of modular applications seamlessly integrates into existing thyroid ultrasound workflows and technology, automating measurements and characterization9,10 and significantly improving workflow efficiency.11 By automating nodule detection, characterization and standardizing worksheets and reporting, Thyroid Suite applications help radiologists and sonographers work more efficiently and consistently. Thyroid Suite builds on organic innovation and technology integrated through the acquisition of See-Mode to deliver a new suite of solutions. Deployment across more than 200 sites within RadNet has demonstrated transformative real-world impact: radiologists interpreting more than 4,070 nodules accepted AI-based measurements and characterization without correction in greater than 94% of the cases.12 The solution supports all ultrasound manufacturers and is available standalone or through the recently announced partnership with GE HealthCare’s ultrasound imaging.
  • DeepHealth Neuro Suite — Quantifying Structural Changes for Proactive Care: The Neuro Suite13 applications automate and standardize neuroimaging analysis. It includes the FDA-cleared applications: Brain Health for white matter hyperintensity (WMH) detection and segmentation and Brain Age for volumetric measurement. By automatically quantifying key structures — including the hippocampus, lobes and subcortical regions — Neuro Suite tracks longitudinal progression to support proactive care.
  • DeepHealth Chest Suite — Stage Shifting Lung Cancer: The applications of the expanded Chest Suite,14 previously referred to as DeepHealth Lung, automate pulmonary nodule detection, characterization and volumetric quantification, as well as standardize reporting and longitudinal tracking. These automations support radiologists in identifying disease earlier and improving diagnostic accuracy,15,16 Chest Suite applications continue to enable population-scale screening programs worldwide, including NHS England’s Lung Cancer Screening Program for which UK Government data show that 76% of detected cancers are now caught at earlier, more treatable stages, compared to only 29% historically.17 Applications within the Chest Suite are cleared in Europe and the UK and are currently US 510(k)-pending, with plans to expand availability to US clinical sites.
  • DeepHealth Prostate Suite — Advancing Diagnosis of Prostate Cancer: The next generation Prostate Suite18 streamlines prostate MRI interpretation, analysis and biopsy planning workflows. The suite integrates automated lesion detection and risk classification (510K pending), intelligent gland segmentation with PSA density calculation, and PI-RADS-compliant reporting into a single platform, delivering diagnostic accuracy19 and standardization of care.19 From initial scan review to targeted biopsy handoff, the solution connects seamlessly with 9+ fusion biopsy systems, eliminating manual data transfer while supporting radiologists at every step. The Suite supports customer programs in the US and was recently selected to support the TRANSFORM prostate screening trial in the UK. 
  • AI Studio — Enabling a Sustainable and Responsible AI Ecosystem: AI Studio, developed in partnership with CARPL and RagaAI, unifies a range of ecosystem AI solutions and enables seamless orchestration of these applications directly within the clinical workflow for automation and AI-powered care. AI Studio can integrate 140+ AI algorithms from 75+ ecosystem vendors, along DeepHealth’s own clinical AI solutions, directly into the worklist, viewer, reporting and workflow engine. The system includes governance tools for AI evaluation, monitoring and drift management in production, ensuring consistent performance and safe, reliable deployment at scale. 

At the core of this portfolio is DeepHealth OS™, a cloud-native operating system that brings together these imaging informatics and AI suites into one unified environment. The OS delivers personalized, role-based experiences with seamless access to clinical and operational data, meeting the needs of every participant in the imaging workflow. With all solutions running on one cloud-native or hybrid platform, deployment, operations, security and infrastructure management are greatly simplified for IT professionals implementing tech solutions in healthcare. 

DeepHealth works with leading OEMs, cloud, AI, and platform partners to unify previously fragmented tools into a connected, end-to-end imaging experience. Elements of DeepHealth’s portfolio are already delivering meaningful impact for patients and healthcare providers around the world, with over 2,000 customers and more than 5,000 radiologists leveraging its current solutions to deliver better care. 

DeepHealth’s portfolio20 is presented in scientific sessions and at Booth #1329, South Hall, Level 3 at McCormick Place in Chicago. Anchoring the space will be an Experience Theater where visitors can experience interactive, hands-on educational lectures illustrating how AI is being integrated into practice across diverse clinical and operational areas. The Theater will also feature live sessions and panel discussions with clinical collaborators, technology partners and research leaders sharing insights from real-world AI deployments and upcoming technological advancements. 

Explore more about DeepHealth’s presence at RSNA 2025 and view the full schedule of live Experience Theater sessions at deephealth.com/rsna

About DeepHealth 
DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, prostate, neuro, and thyroid health. At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. https://deephealth.com 

About RadNet, Inc.
RadNet, Inc. is a leading provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 407 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has about 11,000 team members. https://radnet.com

Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the unifying clinical and operational intelligence into one system and enabling rapid-scale infrastructure that accelerates adoption, our technology becomes a catalyst to stage shift disease, expand patient access, elevate care teams and enhance operational efficiency, discussions regarding our product feature, and statements regarding our recent acquisitions. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet, nor any of its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes, and other risks and uncertainties described in the “Risk Factors,” “Management’s Discussion and Analysis,” and other sections of our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

DeepHealth Media Contact
Andra Axente
Director of Communications
+31614440971
andra.axente@deephealth.com

RadNet Media Contacts
Jane Mazur 
SVP, Corporate Communications
+1 585-355-5978 
jane.mazur@radnet.com 

Mark Stolper
Executive Vice President and Chief Financial Officer
+1 310-445-2800

References 

  1. Diagnostic Suite comprises multiple applications, including DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Any claims made about Diagnostic Suite may reference claims associated with its individual components. 
  2. Data on file. In a pilot deployment at 64 locations inside of RadNet’s New York area facilities, TechLive™ significantly contributed to a 27% increase in advanced breast MRI as a result of using DeepHealth’s TechLive remote scanning capability across 33 MR systems at RadNet NY centers since Feb 2025. 
  3. Breast Suite comprises multiple applications including ProFound Pro, Breast Density, Safeguard Review, Risk Assessment, and DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Risk Assessment is not cleared for use in the U.S. BAC is in development; regulatory submission planned prior to the end of 2025. Not cleared for use in the US. Not all products and functions are available in all markets. Any claims made about Breast Suite may reference claims associated with its individual components.
  4. Louis, L. et al. “Equitable Impact of an AI-Driven Breast Cancer Screening Workflow in Real World US-wide Deployment.” Nature Health, 2025. 
  5. McCabe et al. “Multistage AI-Driven Workflow Improves General Radiologist Screening Mammography Performance to the Level of Fellowship-Trained Breast Imagers: Real-world Evidence in >500,000 Patients.” RSNA Chicago. 2025. 
  6. Not cleared for use in the U.S. Capability available in Europe. 
  7. In development, regulatory submission planned prior to the end of 2025. Not cleared for use in the US. 
  8. DeepHealth Thyroid Suite comprises multiple applications including DeepHealth Viewer and DeepHealth Thyroid AI. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth. DeepHealth Thyroid AI is manufactured as See-Mode Augmented Reporting Tool, Thyroid (SMART-T) by See-Mode and Distributed by DeepHealth Inc. Any claims made about Thyroid Suite may reference claims associated with its individual components.
  9. Data on file. Summary of Performance Testing Studies, Thyroid 510(k) clearance. 
  10. Data on file. “Evaluation of AI-enhanced Thyroid Ultrasound Reporting Software for Improved Diagnostic Consistency.”
  11. Data on file. DeepHealth’s Thyroid AI demonstrated up to a 30% reduction in scan slot time. Initial deployment at RadNet outpatient imaging centers.
  12. Data on file. Results are based on data from 240+ RadNet sites and 22,000 thyroid studies.
  13. Neuro Suite comprises multiple applications including Brain Health, Brain Age and DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD and distributed by DeepHealth. Any claims made about Neuro Suite may reference claims associated with its individual components. Not all products and functions are available in all markets.
  14. Chest Suite comprises multiple applications including Veye Lung Nodules, Veye Reporting, DeepHealth Lung AI, DeepHealth Viewer and HealthCCSng. Veye Lung Nodules and Veye Reporting are manufactured by Aidence B.V. and distributed by DeepHealth, Inc. Neither Veye Lung Nodules nor Veye Reporting are FDA cleared for distribution in the US. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. in the US. HealthCCSng is manufactured by Nanox AI, Ltd. and distributed by DeepHealth, Inc. DeepHealth Lung AI is 510(k) pending. Not all products and functions are available in all markets.
  15. Identifies solid and sub-solid nodules (3-30mm) with 91% sensitivity, 1 false positive per scan. Setio et al. “Validation, comparison, and combination of algorithms for automatic detection of pulmonary nodules….” Med Image Anal. Dec 2017. 
  16. Increases agreement (κ up to 0.82), reduces reading time up to 42%. Hempel et al. “Higher agreement between readers with deep learning CAD software for reporting pulmonary nodules o….” Eur J RadiolOpen. Aug 2022. 
  17. Mouland et al. “Targeted Lung Health Check Programme Final evaluation report.” Ipsos. November 2024.
  18. DeepHealth Prostate Suite comprises multiple applications including Quantib Prostate, DeepHealth Prostate AI and DeepHealth Viewer. Quantib Prostate is Manufactured by Quantib BV and distributed by DeepHealth, Inc, in the US. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. DeepHealth Prostate AI is FDA 510(k) pending. Any claims made about Prostate Suite may reference claims associated with its individual components. Not all products and functions are available in all markets.
  19. Data on file. DeepHealth pivotal study for FDA 510(k) clearance of Prostate AI, 12-reader by 250-case MRMC study and standalone testing on the same 250 exams.
  20. Not all products and functionalities are commercially available in all countries. For clearance and commercial availability in your geography of functionalities listed and compatibility with other systems, please contact a DeepHealth representative.

Anabolic Steroids Alternatives: Muscle Building Supplements from CrazyBulk | Most Selling Muscular Endurance Supplements Bodybuilders Use For Peak Performance & Strength Building in 2025

Anabolic Steroids Alternatives: Muscle Building Supplements from CrazyBulk | Most Selling Muscular Endurance Supplements Bodybuilders Use For Peak Performance & Strength Building in 2025




Anabolic Steroids Alternatives: Muscle Building Supplements from CrazyBulk | Most Selling Muscular Endurance Supplements Bodybuilders Use For Peak Performance & Strength Building in 2025

Discover how CrazyBulk’s Anabolic Steroids Alternatives supplements can enhance muscular endurance, boost strength, and speed up recovery. Learn optimal stacks, training integration tips, and where to buy authentic CrazyBulk Muscle Building Supplements with exclusive bundle offers and guarantees.

New York City, Nov. 29, 2025 (GLOBE NEWSWIRE) —

November 28, 2025, CrazyBulk, a leading provider of Anabolic steroid alternatives, in recent years, fitness enthusiasts have been searching for safer ways to build muscle, gain strength, and speed up recovery without exposing their bodies to the risks of anabolic steroids. This growing demand has led to the development of a new category of supplements known as anabolic steroid alternatives. These products are formulated to offer similar performance benefits but without the harmful side effects associated with synthetic hormones.

Unlike traditional anabolic steroids, these alternatives rely on natural ingredients such as plant extracts, amino acids, vitamins, and minerals to support the body’s own muscle-building processes. They are designed to enhance protein synthesis, boost testosterone naturally, and improve workout performance. For athletes and everyday gym-goers, this means better gains, more energy, and faster recovery—all without breaking any rules or putting long-term health at risk.

One of the biggest advantages is that these alternatives are legal and do not require a prescription. They are widely used by individuals who want results but also value their well-being. Many users appreciate that they can continue training consistently without worrying about liver toxicity, hormone imbalance, or the serious legal consequences linked to anabolic steroid use.

As the fitness industry continues to evolve, natural anabolic alternatives are becoming a preferred choice for responsible athletes. They provide a practical way to stay committed to personal goals while avoiding the dangers of banned substances. For anyone seeking effective, safe, and legal performance support, these modern supplements offer a promising and dependable solution.

Best legal steroid alternatives for Muscular Endurance and Bodybuilding by Crazy Bulk 2025

In this day and age, building muscles can be tough. People are looking for a healthy support system. This quest has given rise to interest in legal steroids for muscle building. Whether they are bodybuilders, professional athletes, or weight lifters, they are looking for muscle building and cutting with no risk of side effects.

Why legal steroids, why not the real steroids? Because steroids are a banned substance. You cannot get steroids without a prescription, and in most professional competitions, it is banned to take steroids. A steroid alternative is a multi-ingredient supplement that works similarly to a steroid, minus the androgenic side effects.

The safest alternative to steroids is the legal steroid alternatives for muscle growth. These products are designed to maximize the muscle-building results, reduce recovery time, cut fat, and improve energy levels. The best part is the low risk of side effects.

The Complete Guide to Bulking and Cutting: How to Build Muscle and Lose Fat the Right Way

Fitness transformation usually happens in two phases: bulking and cutting. These two phases help you build muscle mass, then reduce the fat (preserving the hard-earned muscle mass). When done correctly, the result is an exceptional muscular photogenic build, the top-tier aesthetic, and a lean physique.

Supplements for Muscular Endurance and Bulking

Before we start talking about the supplements, you should know what bulking is. In simple terms, bulking is when you eat more calories than your body needs. Essentially, a caloric surplus diet. The goal is to build muscle and improve strength, and not burn muscle for energy.

The most well-known supplements for bulking are:

Rapid muscle gain is possible with the help of a combo of D-Bal and Testo Max; a few users can add the Tren-max into the mix. The idea here is to maximize protein synthesis and improve the quality and volume.

To get the dense quality volume, you need to lift heavy weights. To lift a heavy weight, you need energy. This energy is derived from the combination of food and supplements. Food is not enough to push your body to its limits.

Another thing your body needs during the muscle-building process is a healthy dose of testosterone. Testosterone plays a major role in metabolism, strength, and vitality. A Natural testosterone Booster helps boost the quality of the workout.

How to stack during bulking?

Most people will need only the D-Bal max, but if you want the rapid muscle gain and get a little bit faster results or have hit a plateau, you can pair D-Bal with Testo-max and Tren-max. All three are bulking products that provide all the support a professional bodybuilder needs. They are almost side-effect-free products.

Nutrition during Bulking

When you’re bulking, it’s all about eating more than you need. You need 300 extra calories a day for lean bulk. For faster bulk, we suggest eating 600 extra calories; this will cause more fat gain.

Don’t do the dirty bulking, where you eat everything in sight. Junk calories are not healthy and will not support rapid muscle growth.

You need 2 grams of protein per kilo of body weight. It is essential for muscle building. 4 to 6 grams per kilo is sufficient.

It is important to add healthy fats to the diet. Your diet should consist of 20 to 30% of daily calories.

Protein sources (chicken breast, lean beef, fish, eggs, salmon, whey protein)

Carbohydrates (Rice, oats, potatoes, pasta, whole grains, fruits)

Healthy fats (Olive oil, peanut butter, Nuts, avocado)

Visit the Official Website to Purchase Or Read More Bulking Stack

Training during Bulking

Key principles:

  • Lift heavy
  • Increase in weight over time
  • Focus on compound movements
  • Higher training volume

Recommended training split:

  • Push / Pull / Legs (PPL)
  • Upper / Lower
  • 5–6 days/week

Include:

  • Squats
  • Deadlifts
  • Bench press
  • Rows
  • Overhead press
  • Pull-ups

Common Mistakes Made during Bulking

  • Don’t eat too much that your stomach cannot handle. Increase your diet gradually and know your limits.
  • No junk calories from fast food and sugary drinks, as they will destroy the muscles.
  • Always track calories to get a good idea
  • Train consistently
  • Get good rest and sleep; recovery is essential during every phase

Supplements for Cutting

Cutting is the opposite of bulking. You eat a calorie-deficient diet to burn the fat gained during bulking while preserving most of the muscle mass gained during bulking. The goal is to get rid of all the fat.

Visit the Official Website to Purchase Or Read More Cutting Stack

NOTE: Cutting is not starving; a good cutting is slow and strategic

The most well-known supplements for cutting made by CrazyBulk are:

Anavarol is best known for muscle retention during the cutting phase. It allows the body to burn fat for energy while preserving muscles. The idea is to boost the metabolism, where your body is burning the extra calories and causing a calorie-deficient diet, which is healthy.

As we have mentioned above, cutting does not equal starvation. Cutting allows the body to improve its aesthetics.

How to stack during cutting?

If you are looking for complete support during the cutting phase, you can pair CrazyBulk’s Anavarol with Clenbutrol and Win-Max. These products will improve the metabolism and have a thermogenic effect, increasing body temperature to burn fat for energy.

Nutrition during Cutting

Along with taking Crazybulk’s Anavarol, you need to take 2.2 grams of protein per kilo of body weight. Compared to bulking, you need extra protein during the cutting phase, which helps retain the muscle built during the bulking phase with the help of CrazyBulk’s D-Bal Max.

Carb consumption should be lowered to 2 to 3 grams per kilo body weight. Crabs add weight; reducing crabs is essential for fat burning.

Fat consumption can remain the same; you decrease it by 5%. However, the amount of healthy fat can stay the same during the bulking and cutting phase.
Protein (Chicken breast, turkey, egg whites, fish, protein shakes)

Low-Calorie nutrient-dense carbs (oats, sweet potato, berries, whole grain, vegetables)

Satiety boosting fibers (soup, Greek yogurt, popcorn in moderate amounts, high-fiber vegetables)

Training during Cutting

Principles:

  • Keep lifting heavy
  • Reduce volume slightly
  • More rest
  • Do NOT switch to only high reps
  • Add cardio carefully

Cardio:

  • 2–4 sessions/week
  • 20–30 minutes
  • Prefer low-intensity steady-state (LISS)

Common mistakes made during Cutting

  • Extreme cutting can lead to muscle loss
  • Don’t overdo cardio, as it can lead to muscle loss
  • Cheat meals, avoid them
  • Avoid junk calories
  • Eat enough protein, if you don’t want to lose muscle

How Long Should Bulking and Cutting Last?

Bulking Phase:

  • Minimum: 8–12 weeks
  • Optimal: 4–8 months
  • Some athletes bulk for a full year (lean bulk)

Cutting Phase:

  • Minimum: 6–8 weeks
  • Optimal: 8–16 weeks
  • Longer cuts (20–24 weeks) for extremely shredded physiques

Bulking lasts longer because building muscle takes more time than losing fat.

Body Fat Levels for Bulking & Cutting

When to Bulk:

  • Men: 10–15% body fat
  • Women: 18–25% body fat

When to Cut:

  • Men: 18–20% body fat+
  • Women: 25–30% body fat+

Benefits of cutting and bulking with the help of CrazyBulk’s D-Bal and Anavarol

Rapid muscle building with minimum risk of side effects

Testo-max has the ability to boost the natural testosterone production, along with muscle building, it will aid in boosting energy levels, improving metabolism, and may have a few benefits for the brain.

An increase in energy levels to improve the muscle quality, volume, and density plays a major role in boosting the overall health quality. It helps build an aesthetically pleasing body.

When you do the bulking stacking of D-Bal Max with Testo-Max and Tren Max, you will maximize the muscle potential. What it means is you will have extra energy to lift heavy, and it may enhance your libido levels. Think of it as the other positive effects of the body.

When you are taking Crazybulk anavarol for cutting, you know it will target the deepest visceral fat and allow you to get a lean physique. It is a confidence booster.

Improved cardiovascular health, the benefit of cutting after bulking, reduces the risk of heart problems by reducing hypertension and cholesterol levels.

Enhanced insulin sensitivity, during the bulking phase when you are eating extra calories, CrazyBulk’s D-Bal plays a major role in maintaining the proper insulin levels to adjust the blood glucose levels.

Increased strength, not just to lift heavy weights in the gym but to perform the day-to-day tasks. You stay active and energetic during the cutting phase.
A metabolic boost with the help of Anavarol from CrazyBulk allows the body to burn extra fat.

A rough plan (25 weeks) that you can use for cutting and bulking with CrazyBulk

Week 1 to 8: Start with bulking if you are thin, or looking to gain muscle and have little fat to lose.

Stack D-Bal Max with Testo-Max and Tren-Max for maximum muscle growth.
Week 9 to 22: Start cutting during this phase, stack the Crazybulk Anavarol with clenbutrol and win-max for maximum muscle retention.

Week 23 – 25: Cycle Therapy is necessary. Take rest during this phase, do not cut or bulk. Allow your body to recuperate from the stress of bulking and cutting.

Sleep and Recovery when you are cutting and bulking with the help of legal steroids alternatives for muscle building

  • Aim for 7 to 9 hours of sleep every night
  • Try to lower the stress
  • Stay hydrated. Doctors suggest drinking 3 to 4 liters of water every day. Try to achieve this goal.
  • Understand the strengths and weaknesses of your body. Don’t overdo the bulking and cutting.
  • Allow your body enough rest to build protein muscle tissue.


Visit the Official Website to Purchase Or Read More Strength Stack

What are the Anabolic Steroids Alternatives for bodybuilding?

The working of CrazyBulk D-Bal Max and Anavarol is simple to understand.
As you know, D-bal is for muscle building during bulking, it enhances the energy levels and lowers the recovery time. The improved strength allows your body to improve the muscle quality, volume, and density. The only downside here is the fat gain, which is normal when you have a calorie surplus diet.

During the cutting phase, when you are on a calorie-deficient diet, you need to preserve the muscles and burn as much fat as you can. Crazybulk Anavarol helps during this phase by boosting the metabolism and initiating something similar to the keto effect. Where your body targets the fat deposit instead of muscles for energy production.

Risk of Side Effects with legal steroids for muscle growth and muscle retention

The risk of side effects is low with legal steroid alternatives. As they are made with herbal alternative ingredients. However, there are a few men who experienced the following complications:

  • Bloating
  • Slow results
  • Nausea
  • Heart palpitations
  • Allergy in rare cases
  • Acne
  • Weakness

Who should use the Anabolic Steroids Alternatives for muscle building and muscle retention?

  • Men who want to maximize the results in the gym
  • Men are facing difficulty in improving the volume density
  • Men who have hit a plateau in muscle building
  • Men who are failing to burn fat after gaining muscle and fat
  • Men who want to supercharge the muscle building and muscle retention

Buying guide legal steroid alternatives:

When you are looking for a legal steroid alternative, you must look for reputable manufacturers like CrazyBulk.

A reputable brand with a loyal and satisfied customer base.

Brands that are using the highest quality ingredients like Crazubulk

Brands that are manufacturing the product in a GMP-certified lab in the USA, like CrazyBulk

Brands that provide the third-party testing data

Brands that are affordable and give realistic results

For all the above reasons, we chose to review CrazyBulk.

Results with Crazybulks legal steroid alternative

It may sound like a cliché, but it is true that Crazy Bulk’s bulking and cutting stack helped me a lot. I was able to gain 7 pounds of muscle and lose 8 pounds of fat. It is essentially one of the best ways for body recomposition. I was not fat to begin with and have an active lifestyle, so this worked really well for me.

I was overweight, so I started with 6 weeks of cutting, followed by 8 weeks of bulking and then 6 weeks of cutting. After that, I took 2 weeks of rest. The results are exceptional. My whole personality has changed. People look at me in a different way. Very happy with the results. I would suggest Crazy Bulk as it works best for muscle building and muscle retention. And FYI, these are not real steroids; you can get them over the counter.”

Final Tips for Success

  • Track calories and macros
  • Focus on long-term body composition
  • Use progressive overload during bulk
  • Be patient—muscle takes time
  • Maintain strength during the cut
  • Avoid extreme diets
  • Eat protein in every meal

Final Thoughts on the Legal steroid alternative for muscle Endurance (cutting and bulking)

The legal steroid alternative, especially from the brand Crazybulk, is worth trying. These products will aid in improving the results without reducing the quality of life. These are not real steroids; they don’t have the androgenic side effects. The customer experience with the products is generally favorable. If you can follow the healthy diet along with the bulking stack of D-Bal Max and Testo Max with ten max and the cutting stack of Anavarol with Clenbutrol, you are bound to get good results. Buy the products from the official website to avoid counterfeit products. Hard work and legal steroids can help you get the Instagram-worthy physique. Crazy Bulk also launches SARMS alternatives for bulking, cutting, and bodybuilding.

Manufactured under the Technical Guidance of:

Project name: Crazybulk

Official Website: https:://www.crazybulk.com/

244 Madison Avenue,

New York City, NY 10016-2817

Postal code: NY 10016-2817

Media Contact:

Full Name – Neil Bowers

email: support@crazybulk.com

+1 888-708-6394

Contact Us for Advertising: Info@allprsolution.com

Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program

Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program




Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program

VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, announces that further to its news release dated June 30, 2025, and in accordance with the terms of a debenture indenture (the “Indenture”) between the Company and Odyssey Trust Company as the debenture trustee (the “Debenture Trustee”) dated May 29, 2023, governing the 12.0% convertible debentures of the Company in the aggregate principal amount of $1,454,000.00 (the “Convertible Debentures“), holders (each, a “Debentureholder“) representing at least 66 2/3% of the outstanding principal of the Convertible Debentures have consented to the extension of the maturity date of the Convertible Debentures from November 29, 2025 to January 28, 2026 (the “Extension”). The Extension was approved by way of a written consent dated November 28, 2025, in accordance with the terms of the Indenture. At this time, the Company has not proceeded with the amendments referenced in the June 30, 2025, news release.

Amendment of Convertible Debentures

The Company proposes to execute a supplemental indenture with the Debenture Trustee amending the terms of the Indenture to reflect the Extension. All other terms will remain the same and the Convertible Debentures will continue to bear interest at a rate of 12.0% during the Extension. The Extension remains subject to the approval of the TSX Venture Exchange (the “Exchange”).

Related Party Disclosure

Certain directors of the Company, as a group, beneficially own, control or direct, directly, or indirectly, approximately $100,000 principal amount of the Convertible Debentures, representing approximately 6.9% of the outstanding principal amount of the Convertible Debentures. Participation by such persons in the Extension constituted a “related party transaction” as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“) and Exchange Policy 5.9 – Protection of Minority Security Holders in Special Transactions (“Policy 5.9“). The Company relied on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) thereof, as neither the fair market value of the Convertible Debentures held by related parties, nor the consideration payable in respect thereof, exceeded 25% of the Company’s market capitalization.

Warrant Incentive Program

Further to the Company’s new release dated July 24, 2025, the Company also announces that its early exercise warrant incentive program expired on September 2, 2025, and no warrants were exercised.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.

The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at www.rakovinatherapeutics.com.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Notice Regarding Forward-Looking Statements

This press release may contain “forward-looking statements” regarding the Company and its respective business within the meaning of applicable Canadian securities laws, including, without limitations, statements regarding: receipt of Exchange approval; the Company’s objectives, goals, or future plans regarding its cancer treatments or proposed business plan and expected results of the Company’s DDR platform. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic, and competitive uncertainties and contingencies. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.

The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

The reader is referred to the Company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedarplus.ca.

For Further Information Contact:

Michelle Seltenrich, BSc MBA
Director, Corporate Development
IR@rakovinatherapeutics.com
778-773-5432

Algernon Closes Second Tranche of Private Placement Financing

Algernon Closes Second Tranche of Private Placement Financing




Algernon Closes Second Tranche of Private Placement Financing

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR 
FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) — Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces the closing of the second tranche (the “Second Tranche”) of its non-brokered private placement (the “Offering”), previously announced on November 6, 2025, with the first tranche closed on November 14, 2025. Gross proceeds from the Second Tranche totaled CAD $210,000 from the sale of 3,000,000 units (the “Units”) at an issue price of CAD $0.07 per Unit.

The Company did not pay any cash finder’s fees pertaining to the Second Tranche of the Offering.

The Company will use the proceeds of the Offering towards advancing its Alzheimer’s Disease (“AD”) program including the opening of its first U.S. AD clinic, general and administrative expenses and for working capital purposes.

The securities issued and issuable, described in this and the previous news release on November 6, 2025, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration

For more information, please contact:

Christopher J. Moreau
CEO
Algernon Health Inc.
604.398.4175 Ext 701

cjmoreau@algernonhealth.com

https://www.algernonhealth.com/

About Algernon Health  

Algernon Health is a Canadian healthcare company focused on the provision of brain optimized PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer’s Disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. Algernon is also the parent company of a recently created private subsidiary called Algernon USA LLC, that will oversee all U.S. neuroimaging operations.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to planned brain-specific neuroimaging PET scanning clinic opening timelines, planned financings in the Company and its subsidiary and the closings of additional tranches thereof, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.